Condition (MeSH)
Severe Dengue
ClinicalTrials.gov lists 65 trials for Severe Dengue or a narrower condition beneath it. Sanofi Pasteur, a Sanofi Company has the most among industry and government lead sponsors, with 25.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
65 of the 65 trials are tagged with Severe Dengue itself; the rest are tagged with a narrower condition beneath it.
When did Severe Dengue trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 8 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Severe Dengue trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 20 |
| Phase 2/3 | 1 |
| Phase 3 | 12 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 13 |
How many Severe Dengue trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 53 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Severe Dengue trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sanofi Pasteur, a Sanofi Company | 25 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 13 |
| Sanofi | 4 |
| U.S. Army Medical Research and Development Command | 3 |
| Hawaii Biotech, Inc. | 1 |
Showing 5 of 6 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| CYD Dengue Vaccine | 11 |
| Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus | 4 |
| rDEN1delta30 | 3 |
| Live, attenuated, dengue serotype 1, 2, 3, 4 virus | 2 |
| 1 µg TDENV-PIV with Alum adjuvant | 2 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Severe Dengue trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dengue Fever | 598 | 4 |
| Appendicitis | 501 | 14 |
| Road Traffic Accident | 262 | 5 |
| Gastroenteritis | 226 | 12 |
| Urinary Tract Infection | 215 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Severe Dengue? (68)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Temporal cytokine storm dynamics in dengue infection predicts severity. | Virus research | 2024 | Yes |
| Effect of montelukast in preventing dengue with warning signs among patients with dengue: A multicenter, randomized, double-blind, placebo-controlled trial. | PLoS neglected tropical diseases | 2024 | Yes |
| Associated risk factors of severe dengue in Reunion Island: A prospective cohort study. | PLoS neglected tropical diseases | 2023 | Yes |
| Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine. | BMC infectious diseases | 2023 | Yes |
| A modified Sequential Organ Failure Assessment score for dengue: development, evaluation and proposal for use in clinical trials. | BMC infectious diseases | 2022 | Yes |
Showing 5 of 68 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.